Screener
10x Genomics, Inc. TXG Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (9,694) | (2,891) |
| Operating lease liability | (5,826) | (4,986) |
| Other noncurrent liabilities | 90 | 1,040 |
| Net cash provided by operating activities | 43,094 | 52,059 |
| Investing activities: | ||
| Business combination | (6,101) | — |
| Purchases of property and equipment | (3,185) | (3,471) |
| Purchases of marketable securities | (49,260) | (49,361) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s operating cash flow?
- 10x Genomics, Inc. (TXG) reported operating cash flow of $16.97M in Q2 2026.
- How has 10x Genomics, Inc.'s operating cash flow changed year-over-year?
- 10x Genomics, Inc.'s operating cash flow decreased by 4.1% year-over-year, from $17.71M to $16.97M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about 10x Genomics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude